US Stock MarketDetailed Quotes
PROK ProKidney
- 1.795
- -0.085-4.52%
Close Dec 13 16:00 ET
- 1.800
- +0.005+0.28%
Post 18:08 ET
229.70MMarket Cap-3.32P/E (TTM)
1.890High1.700Low499.44KVolume1.890Open1.880Pre Close879.37KTurnover0.71%Turnover RatioLossP/E (Static)127.97MShares4.44052wk High-0.23P/B126.35MFloat Cap1.18052wk Low--Dividend TTM70.39MShs Float14.190Historical High--Div YieldTTM10.11%Amplitude1.120Historical Low1.760Avg Price1Lot Size
ProKidney Stock Forum
Sign in to post a comment
$ProKidney (PROK.US)$
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...
1
1
$ProKidney (PROK.US)$ ProKidney | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Aaron Cowen(10.47%),Suvretta Capital Management, LLC(9.8%), etc.
SEC· 11 mins ago
SEC· 11 mins ago
$ProKidney (PROK.US)$ Today announced that the Company will present five posters, including one late-breaking clinical trial, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held on October 23-27, 2024, in San Diego, CA.
1
$ProKidney (PROK.US)$ Reuters· 2 mins ago
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
2
$ProKidney (PROK.US)$ ProKidney Announces the Closing of $140 Million Public Offering of Class a Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
2
$ProKidney (PROK.US)$
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
2
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
MARKET-TEST-DUMMY OP : 8% today not bad